I am a professor and director of molecular epidemiology at Cedars-Sinai. My research program is focused largely on understanding the underlying causes of ovarian cancer initiation and development. I have a long, established track record in defining the heritable component of ovarian cancer, and the functional role of both common and rare risk variants and their target susceptibility genes in the early-stage disease pathogenesis. The overall approach of this research program is to integrate genomics and epigenomics analyses to identify molecular markers associated with disease, with cell biology modeling studies to validate the role of novel molecular markers in disease biology. The goal is to translate the findings from these studies into the clinical arena to improve risk prediction and prevention strategies, early-stage screening and disease diagnosis and targeted therapeutics for patients.
- Cell Biology and Molecular Carcinogenesis Working Group
- Genetic Epidemiology and Variant Discovery Working Group
- Understanding How Ovarian Cancer Risk Loci Increase Disease Risk
- Identifying How Ovarian Cancer Risk Loci Affect Disease Biology
- Mapping Novel Variants for Ovarian Cancer
- Functional Genomics and GWAS Working Group
- Identification of Functional Variants in Ovarian GWAS Regions
- Identifying Candidate Susceptibility Genes Associated with Prostate, Breast and Ovarian Cancer Risk Loci
Learn more about the scientists, faculty members, investigators and other healthcare professionals of the Gayther Laboratory, whose dedicated efforts lead to groundbreaking discoveries.
Manek R, Pakzamir E, Mhawech-Fauceglia P, Pejovic T, Sowter H, Gayther SA, Lawrenson K.
Oncogenesis. 2016 Aug;5(8):e251.
Adler EK, Mhawech-Fauceglia P, Gayther SA, Lawrenson, K.
Hum Pathol. 2015 Jul;46(7):948-956.
Lawrenson K, Lee N, Torres HA, Lee JM, Brueggmann D, Rao N, Noushmehr H, Gayther SA.
Gynecol Oncol. 2014 Oct;135(1):100-107.